NASDAQ:CMPX Compass Therapeutics (CMPX) Stock Forecast, Price & News $1.87 -0.05 (-2.60%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$1.83▼$1.9250-Day Range$1.92▼$2.9352-Week Range$1.81▼$5.65Volume295,496 shsAverage Volume419,261 shsMarket Capitalization$238.35 millionP/E RatioN/ADividend YieldN/APrice Target$9.05 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Compass Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside384.0% Upside$9.05 Price TargetShort InterestBearish5.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.38) to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector440th out of 961 stocksBiological Products, Except Diagnostic Industry67th out of 159 stocks 3.5 Analyst's Opinion Consensus RatingCompass Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.05, Compass Therapeutics has a forecasted upside of 384.0% from its current price of $1.87.Amount of Analyst CoverageCompass Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.45% of the float of Compass Therapeutics has been sold short.Short Interest Ratio / Days to CoverCompass Therapeutics has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Compass Therapeutics has recently decreased by 1.12%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCompass Therapeutics does not currently pay a dividend.Dividend GrowthCompass Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMPX. Previous Next 1.1 News and Social Media Coverage Search Interest3 people have searched for CMPX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Compass Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders30.00% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.01% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.38) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Therapeutics is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Therapeutics is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompass Therapeutics has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Compass Therapeutics (NASDAQ:CMPX) StockCompass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.Read More CMPX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMPX Stock News HeadlinesAugust 24, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn SituationAugust 3, 2023 | msn.comHC Wainwright & Co. Reiterates Compass Therapeutics (CMPX) Buy RecommendationSeptember 21, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.August 3, 2023 | msn.comCompass Therapeutics GAAP EPS of -$0.09August 3, 2023 | finance.yahoo.comCompass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJune 22, 2023 | msn.comCompass Therapeutics added to Russell indexesJune 22, 2023 | finance.yahoo.comCompass Therapeutics to be Added to the Russell 2000® and Russell 3000® IndexesJune 22, 2023 | finance.yahoo.comCompass Therapeutics to be Added to the Russell 2000® and Russell 3000® IndexesSeptember 21, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.June 1, 2023 | finance.yahoo.comCompass Therapeutics to Participate in Upcoming Investor EventsMay 10, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Compass Therapeutics (CMPX)May 4, 2023 | msn.comCompass Therapeutics: Q1 Earnings InsightsMay 4, 2023 | finance.yahoo.comCompass Therapeutics Reports First Quarter Financial Results and Provides Corporate UpdateApril 26, 2023 | finance.yahoo.comCompass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQApril 25, 2023 | usnews.comFrequently Asked Questions: U.S. News College CompassApril 19, 2023 | finance.yahoo.comCompass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology DaysApril 13, 2023 | finance.yahoo.comWith 55% ownership of the shares, Compass Therapeutics, Inc. (NASDAQ:CMPX) is heavily dominated by institutional ownersMarch 28, 2023 | finance.yahoo.comCompass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology SymposiumMarch 17, 2023 | seekingalpha.comCompass Therapeutics GAAP EPS of -$0.10March 17, 2023 | finance.yahoo.comWe're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash WiselyMarch 15, 2023 | finance.yahoo.comCompass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateFebruary 15, 2023 | seekingalpha.comCMPX Compass Therapeutics, Inc.February 2, 2023 | finance.yahoo.comCompass Therapeutics to Participate in the SVB Securities Global Biopharma ConferenceJanuary 27, 2023 | msn.comBenzinga's Top Ratings Upgrades, Downgrades For January 27, 2023January 27, 2023 | markets.businessinsider.comExpert Ratings for Compass TherapeuticsJanuary 26, 2023 | yahoo.comCo-Founder Thomas Schuetz Just Bought A Handful Of Shares In Compass Therapeutics, Inc. (NASDAQ:CMPX)January 24, 2023 | msn.comCompass Therapeutics added to Wedbush Best Ideas List on lead cancer candidateSee More Headlines Receive CMPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPX Company Calendar Last Earnings8/03/2023Today9/21/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CMPX CUSIPN/A CIK1738021 Webwww.compasstherapeutics.com Phone617-500-8099FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.05 High Stock Price Forecast$10.30 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+376.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.62% Return on Assets-24.58% Debt Debt-to-Equity RatioN/A Current Ratio18.07 Quick Ratio18.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.44 per share Price / Book1.32Miscellaneous Outstanding Shares127,460,000Free Float89,221,000Market Cap$242.17 million OptionableNot Optionable Beta0.71 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Thomas J. Schuetz M.D. (Age 62)Ph.D., Co-Founder, CEO & Director Comp: $829.56kDr. Vered Bisker-Leib M.D. (Age 52)MBA, Ph.D., Pres & COO Comp: $806.43kMr. Neil L. Lerner CPA (Age 56)VP of Fin. Mr. Jonathan Anderman J.D.VP, Head of Legal & Corp. Sec.Anna GiffordCommunications Mang.Dr. Minori Rosales M.D. (Age 60)Ph.D., Sr. VP & Head of Clinical Devel. Ms. Karin Herrera B.A.VP & Head of Clinical OperationsDr. James Kranz Ph.D.VP and Head of Chemistry Manufacturing & ControlsMore ExecutivesKey CompetitorsAlloVirNASDAQ:ALVRZura BioNASDAQ:ZURAVigil NeuroscienceNASDAQ:VIGLDBV TechnologiesNASDAQ:DBVTScilexNASDAQ:SCLXView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemBought 30,732 shares on 8/21/2023Ownership: 0.076%Stifel Financial CorpBought 15,000 shares on 8/15/2023Ownership: 0.012%Royal Bank of CanadaBought 11,793 shares on 8/15/2023Ownership: 0.010%Alliancebernstein L.P.Bought 11,260 shares on 8/15/2023Ownership: 0.009%XTX Topco LtdBought 10,992 shares on 8/15/2023Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions CMPX Stock - Frequently Asked Questions Should I buy or sell Compass Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CMPX shares. View CMPX analyst ratings or view top-rated stocks. What is Compass Therapeutics' stock price forecast for 2023? 5 equities research analysts have issued 12-month price objectives for Compass Therapeutics' shares. Their CMPX share price forecasts range from $8.00 to $10.30. On average, they predict the company's share price to reach $9.05 in the next twelve months. This suggests a possible upside of 376.3% from the stock's current price. View analysts price targets for CMPX or view top-rated stocks among Wall Street analysts. How have CMPX shares performed in 2023? Compass Therapeutics' stock was trading at $5.03 on January 1st, 2023. Since then, CMPX shares have decreased by 62.2% and is now trading at $1.90. View the best growth stocks for 2023 here. When is Compass Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our CMPX earnings forecast. How were Compass Therapeutics' earnings last quarter? Compass Therapeutics, Inc. (NASDAQ:CMPX) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. When did Compass Therapeutics IPO? (CMPX) raised $50 million in an initial public offering (IPO) on the week of November 16th 2020. The company issued 9,000,000 shares at $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel acted as the underwriters for the IPO and Raymond James was co-manager. What is Compass Therapeutics' stock symbol? Compass Therapeutics trades on the NASDAQ under the ticker symbol "CMPX." Who are Compass Therapeutics' major shareholders? Compass Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.73%), Braidwell LP (4.67%), Monashee Investment Management LLC (1.55%), Geode Capital Management LLC (1.42%), State Street Corp (1.37%) and Foresite Capital Management V LLC (1.04%). Insiders that own company stock include Carl L Gordon, Orbimed Advisors Llc, Thomas J Schuetz and Vered Bisker-Leib. View institutional ownership trends. How do I buy shares of Compass Therapeutics? Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Compass Therapeutics' stock price today? One share of CMPX stock can currently be purchased for approximately $1.90. How much money does Compass Therapeutics make? Compass Therapeutics (NASDAQ:CMPX) has a market capitalization of $242.17 million. The company earns $-39,220,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. How can I contact Compass Therapeutics? The official website for the company is www.compasstherapeutics.com. The company can be reached via phone at 617-500-8099 or via email at ir@compasstherapeutics.com. This page (NASDAQ:CMPX) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.